NCT02440685 - A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

June 30, 2018

Study Completion Date

July 31, 2018

Conditions

Lymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellLymphoma, FollicularCancerNeoplasmTumorLymphoma, MalignantLymphoma, B-cellLymphoma, Non-HodgkinB-Cell Chronic Lymphocytic LeukemiaB-Cell Leukemia, ChronicB-Lymphocytic Leukemia, ChronicChronic Lymphocytic LeukemiaLeukemia, Lymphocytic, ChronicLeukemia, Lymphocytic, Chronic, B CellMyelofibrosisChronic Idiopathic MyelofibrosisIdiopathic MyelofibrosisLymphoma, T Cell, PeripheralPeripheral T-Cell LymphomaT-Cell Lymphoma, Peripheral

Interventions

DRUG

ASN002 Dose Escalation

Multiple ascending doses of ASN002 assigned by cohort

DRUG

ASN002 RD

Recommended dose of ASN002 from Part A

Trial Locations (14)

1426

Instituto Alexander Fleming, Buenos Aires

1629

Hospital Universitario Austral, Buenos Aires

19111

Fox Chase Cancer Center, Philadelphia

22031

Virginia Cancer Specialists, Fairfax

30322

Winship Cancer Institute - Emory, Atlanta

39216

University of Mississippi Medical Center, Jackson

44718

Gabrail Cancer Center, Canton

48109

University of Michigan, Ann Arbor

49546

START - Midwest, Grand Rapids

77030

MD Anderson Cancer Center, Houston

78229

South Texas Accelerated Research Therapeutics, San Antonio

85284

Arizona Oncology, Tempe

94143

University of California, San Francisco, San Francisco

97239

Oregon Health & Science University, Portland